Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CRBP Corbus Pharmaceuticals Holdings Inc
- Stocks
- Healthcare
- NASDAQ: CRBP
Price (delayed)
$7.47
Market cap
$91.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.2
Enterprise value
$74.69M
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company's lead product candidate, lenabasum, is
Highlights
CRBP's debt has dropped by 83% year-on-year and by 12% since the previous quarter
The quick ratio has soared by 147% YoY but it fell by 9% QoQ
Corbus Pharmaceuticals Holdings's EPS has increased by 39% YoY but it has decreased by 14% QoQ
Corbus Pharmaceuticals Holdings's net income has decreased by 49% YoY and by 25% from the previous quarter
Key stats
What are the main financial stats of CRBP
Market
Valuations
Earnings
Shares outstanding
12.24M
Market cap
$91.41M
Enterprise value
$74.69M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.72
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$58.87M
Net income
-$50.29M
EBIT
-$49.26M
EBITDA
-$48.74M
Free cash flow
-$50.25M
Per share
Balance sheet
Liquidity
EPS
-$4.2
EPS diluted
-$4.2
Free cash flow per share
-$4.12
Book value per share
$10.39
Revenue per share
$0
TBVPS
$11.47
Total assets
$139.93M
Total liabilities
$12.83M
Debt
$2.86M
Equity
$127.11M
Working capital
$125.74M
Debt to equity
0.02
Current ratio
11.82
Quick ratio
11.49
Net debt/EBITDA
0.34
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-32.9%
Return on equity
-36.9%
Return on invested capital
-39.8%
Return on capital employed
-38.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRBP stock price
How has the Corbus Pharmaceuticals Holdings stock price performed over time
Intraday
-3.74%
1 week
2.89%
1 month
23.88%
1 year
-84.61%
YTD
-36.69%
QTD
40.68%
Financial performance
How have Corbus Pharmaceuticals Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$58.87M
Net income
-$50.29M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 57% year-on-year and by 21% since the previous quarter
Corbus Pharmaceuticals Holdings's net income has decreased by 49% YoY and by 25% from the previous quarter
Price vs fundamentals
How does CRBP's price correlate with its fundamentals
Growth
What is Corbus Pharmaceuticals Holdings's growth rate over time
Valuation
What is Corbus Pharmaceuticals Holdings stock price valuation
P/E
N/A
P/B
0.72
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Corbus Pharmaceuticals Holdings's EPS has increased by 39% YoY but it has decreased by 14% QoQ
CRBP's P/B is 90% below its 5-year quarterly average of 7.5 and 58% below its last 4 quarters average of 1.8
The company's equity rose by 31% YoY but it fell by 11% QoQ
Efficiency
How efficient is Corbus Pharmaceuticals Holdings business performance
The ROE has soared by 73% YoY but it fell by 18% QoQ
CRBP's return on invested capital is up by 46% year-on-year but it is down by 26% since the previous quarter
The ROA has increased by 43% YoY but it has decreased by 22% from the previous quarter
Dividends
What is CRBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRBP.
Financial health
How did Corbus Pharmaceuticals Holdings financials performed over time
Corbus Pharmaceuticals Holdings's current ratio has surged by 152% YoY but it has decreased by 9% QoQ
The quick ratio has soared by 147% YoY but it fell by 9% QoQ
CRBP's debt is 98% smaller than its equity
CRBP's debt to equity has dropped by 89% year-on-year
CRBP's debt has dropped by 83% year-on-year and by 12% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.